PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22084166-5	2012	The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation.	SU 11657	21-28	fms related receptor tyrosine kinase 3	Homo sapiens	4-9
22084166-5	2012	The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation.	SU 11657	21-28	vascular endothelial growth factor A	Homo sapiens	52-56
22084166-5	2012	The FLT-3 inhibitor, SU11657, significantly reduced VEGF secretion in three of six xenograft lines and MV4;11 cells, in conjunction with inhibition of FLT-3 tyrosine phosphorylation.	SU 11657	21-28	fms related receptor tyrosine kinase 3	Homo sapiens	151-156
22084166-7	2012	In terms of downstream signaling, SU11657 and D43 both caused dephosphorylation of extracellular signal-regulated kinase 1/2, with no changes in AKT or STAT5 phosphorylation.	SU 11657	34-41	mitogen-activated protein kinase 3	Homo sapiens	83-124
20435347-0	2010	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.	SU 11657	124-131	fms related receptor tyrosine kinase 3	Homo sapiens	0-4
20435347-0	2010	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.	SU 11657	124-131	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	9-12
20435347-6	2010	FLT3 and KIT mutated samples were significantly more sensitive to SU11657 than WT KIT and FLT3 samples.	SU 11657	66-73	fms related receptor tyrosine kinase 3	Homo sapiens	0-4
20435347-6	2010	FLT3 and KIT mutated samples were significantly more sensitive to SU11657 than WT KIT and FLT3 samples.	SU 11657	66-73	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	9-12
20435347-7	2010	Samples without KIT or FLT3 mutations, but with a high wild-type (WT) KIT expression were significantly more sensitive to SU11657 than samples with low KIT expression.	SU 11657	122-129	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	70-73
20435347-7	2010	Samples without KIT or FLT3 mutations, but with a high wild-type (WT) KIT expression were significantly more sensitive to SU11657 than samples with low KIT expression.	SU 11657	122-129	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	70-73
15718357-2	2005	SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors (PDGFR), VEGF receptors (VEGFR), stem cell factor receptor (c-KIT), and FMS-related tyrosine kinase 3.	SU 11657	0-7	platelet derived growth factor receptor, beta polypeptide	Mus musculus	151-156
15867359-3	2005	We found that in vitro and in vivo, the antiendothelial and antitumor effects of the triple therapy combination consisting of SU11657 (a multitargeted small molecule inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases), Pemetrexed (a multitargeted folate antimetabolite), and ionizing radiation were superior to all single and dual combinations.	SU 11657	126-133	vascular endothelial growth factor A	Homo sapiens	179-213
18234428-1	2008	PURPOSE: To analyze the effect of the multireceptor tyrosine kinase inhibitor SU11657 (primarily vascular endothelial growth factor, platelet-derived growth factor) in combination with irradiation in freshly isolated primary human meningioma cells.	SU 11657	78-85	vascular endothelial growth factor A	Homo sapiens	97-131
17184839-0	2007	Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.	SU 11657	35-42	FMS-like tyrosine kinase 3	Mus musculus	20-24
17184839-2	2007	We used our model of APL with activated FLT3 to assess the effectiveness of chemotherapy in combination with SU11657, an inhibitor of FLT3.	SU 11657	109-116	neuraminidase 1	Mus musculus	21-24
17184839-2	2007	We used our model of APL with activated FLT3 to assess the effectiveness of chemotherapy in combination with SU11657, an inhibitor of FLT3.	SU 11657	109-116	FMS-like tyrosine kinase 3	Mus musculus	134-138
17483364-8	2007	Furthermore, the receptor tyrosine kinase inhibitor, SU11657, completely reversed dexamethasone resistance in a xenograft expressing functional GR, indicating that pharmacologic reversal of glucocorticoid resistance in childhood ALL is achievable.	SU 11657	53-60	nuclear receptor subfamily 3 group C member 1	Homo sapiens	144-146
16148112-3	2005	In the present study, we show that SU11657, a small multitargeted receptor tyrosine kinase inhibitor with Flt3 affinity, suppressed in vitro natural IFN-producing and DC development in Flt3L-supplemented mouse whole bone marrow cell cultures in a dose-dependant manner, while DC development in GM-CSF-supplemented cultures was not affected.	SU 11657	35-42	FMS-like tyrosine kinase 3	Mus musculus	106-110
16148112-3	2005	In the present study, we show that SU11657, a small multitargeted receptor tyrosine kinase inhibitor with Flt3 affinity, suppressed in vitro natural IFN-producing and DC development in Flt3L-supplemented mouse whole bone marrow cell cultures in a dose-dependant manner, while DC development in GM-CSF-supplemented cultures was not affected.	SU 11657	35-42	FMS-like tyrosine kinase 3 ligand	Mus musculus	185-190
16148112-3	2005	In the present study, we show that SU11657, a small multitargeted receptor tyrosine kinase inhibitor with Flt3 affinity, suppressed in vitro natural IFN-producing and DC development in Flt3L-supplemented mouse whole bone marrow cell cultures in a dose-dependant manner, while DC development in GM-CSF-supplemented cultures was not affected.	SU 11657	35-42	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	294-300
15718357-2	2005	SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors (PDGFR), VEGF receptors (VEGFR), stem cell factor receptor (c-KIT), and FMS-related tyrosine kinase 3.	SU 11657	0-7	vascular endothelial growth factor A	Mus musculus	159-163
15718357-2	2005	SU11657 (SUGEN) is a selective multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity exerted by targeting PDGF receptors (PDGFR), VEGF receptors (VEGFR), stem cell factor receptor (c-KIT), and FMS-related tyrosine kinase 3.	SU 11657	0-7	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	210-215
15718357-3	2005	Oral administration of SU11657 at 40 mg x kg(-1) x d(-1) to athymic mice resulted in significant growth inhibition of a panel of s.c. human neuroblastoma xenografts, namely, fast-growing SK-N-AS, MYCN- amplified IMR-32, and SH-SY5Y, by 90, 93.8, and 88%, respectively, and was well tolerated.	SU 11657	23-30	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	196-200
15044254-0	2004	Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.	SU 11657	114-121	ets variant 6	Mus musculus	22-25
15044254-0	2004	Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.	SU 11657	114-121	platelet derived growth factor receptor, beta polypeptide	Mus musculus	26-32
15044254-2	2004	SU11657 is a multitargeted selective inhibitor of class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors KIT and FLT3.	SU 11657	0-7	vascular endothelial growth factor A	Mus musculus	145-179
15044254-2	2004	SU11657 is a multitargeted selective inhibitor of class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors KIT and FLT3.	SU 11657	0-7	vascular endothelial growth factor A	Mus musculus	181-185
15044254-2	2004	SU11657 is a multitargeted selective inhibitor of class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors KIT and FLT3.	SU 11657	0-7	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	197-200
15044254-2	2004	SU11657 is a multitargeted selective inhibitor of class III/V receptor tyrosine kinases, including the platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) receptors KIT and FLT3.	SU 11657	0-7	FMS-like tyrosine kinase 3	Mus musculus	205-209
15044254-3	2004	SU11657 inhibited TEL/PDGFbetaR kinase activity at nanomolar concentrations and inhibited TELPDGFRB-mediated factor-independent growth in myeloblastic 32D cells.	SU 11657	0-7	ets variant 6	Mus musculus	18-21
12515727-0	2003	A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.	SU 11657	107-114	fms related receptor tyrosine kinase 3	Homo sapiens	20-24
12515727-9	2003	SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT3, cooperated with all-trans retinoic acid to rapidly cause regression of leukemia.	SU 11657	0-7	fms related receptor tyrosine kinase 3	Homo sapiens	81-85